Keywords: phase, ii, study, idec, anticancer, antibody, pharmaceuticals

Phase II Study of IDEC Anticancer Antibody

Article | 13 November 1995

Print This

IDEC Pharmaceuticals has revealed results of a Phase II trial of its anti-CD20 antibody IDEC-C2B8, in combination with a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in